Jonah Feldman

From 2013 to 2022, the rate of important identified risks associated with ponatinib in the treatment of those with ALL or CML had decreased.

Real-world data show that CAR T-cell therapy may be considered for eligible patients with relapsed/refractory multiple myeloma harboring CNS involvement.

Pelabresib and ruxolitinib combination maintains consistent reduction of symptoms and anemia in patients with myelofibrosis.

Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.

QOL data from DESTINY-Breast06 support T-DXd as a new therapeutic option in previously treated HER2-low and HER2-ultralow metastatic breast cancer.

Phase 1/2 data support further development of ARV-766 in advanced prostate cancer, says Daniel P. Petrylak, MD.

Limited efficacy was observed when sacituzumab govitecan was given after enfortumab vedodin in metastatic urothelial carcinoma.

Immune engager therapies, if available, should be considered as a first treatment choice following idecabtagene vicleucel treatment in multiple myeloma, according to Murali Janakiram, MD, MS.

Approximately a third of patients with chronic graft-versus-host disease remain on treatment with ruxolitinib for a median of 389 days, according to findings from a retrospective study.

Results from a post hoc sensitivity analysis of the phase 3 ARASENS trial appear to affirm the primary overall survival analysis findings.

Treatment outcomes with obecabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia appear to be better in those with lower leukemia burden at lymphodepletion in the FELIX study.

Trastuzumab deruxtecan produces the longest time to next treatment in patients with HER2-positive or stable HER2-low advanced breast cancer in the RELIEVE study.

Investigators will continue to assess the efficacy and safety of lenvatinib plus pembrolizumab and chemotherapy as frontline treatment for patients with metastatic esophageal squamous cell carcinoma in part 2 of the LEAP-014 study.

Durcabtagene autoleucel shows robust expansion in vivo followed by persistence in approximately half of patients with relapsed/refractory multiple myeloma enrolled on a phase 1 trial.

The safety of fianlimab plus cemiplimab appears consistent with the safety profile previously observed with each individual agent among patients with previously treated metastatic melanoma in a phase 1 study.

Germline and somatic BRCA1/2 alterations correlate with worse survival in patients with metastatic castration-resistant prostate cancer in the CAPTURE trial.

Patients with unresectable hepatocellular carcinoma experienced an improvement in several health-related quality of life measures following treatment with first-line tislelizumab compared with sorafenib.

Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer did not derive further benefit when palbociclib was added to fulvestrant.

Trastuzumab deruxtecan demonstrates clinically meaningful benefit in patients with non¬–small cell lung cancer harboring HER2 mutations, according to results from the DESTINY-Lung02 trial.

Follow-up to the phase 2 NAVIGATE and phase 1 LOXO-TRK-14001 trials showed durable responses and extended survival in patients with NTRK fusion–positive lung cancer who were treated with larotrectinib.

Adding irinotecan to chemotherapy plus panitumumab for treatment of metastatic colorectal cancer did not result in a significant impact on efficacy.

The 5-year analysis of the phase 3 CheckMate 227 trial showed consistent, long-term survival with nivolumab plus ipilimumab for metastatic non–small cell lung cancer.

Adverse effects were found to be similar between patients with metastatic hormone-sensitive prostate cancer who were treated with darolutamide plus androgen deprivation therapy and docetaxel vs androgen deprivation therapy and docetaxel alone.

Topical ruxolitinib cream resulted in benefit to patients with cutaneous chronic graft-vs-host based on results of a trial that were presented at the 2022 Tandem Meeting.

Investigators uncovered potential mechanisms of resistance to CD19-directed CAR T-cell therapy in patients with pediatric acute lymphoblastic leukemia.

The CAR T-cell product BNT211 when used with or without a CAR T cell–amplifying RNA vaccine produced considerable responses and safety in patients with CLDN6-positive advanced solid tumors.

Data from a phase 2 trial of atezolizumab with or without radiotherapy showed some antitumor activity in advanced squamous cell carcinoma of the penis, despite failing to meet the primary end point of progression-free survival.

Although sintilimab improved overall response rates and maintained a tolerable safety profile for patients with metastatic or recurrent pancreatic adenocarcinoma, it did not improve overall or progression-free survival.

Acalabrutinib produced positive quality-adjusted survival benefits over other treatment options for patients with relapsed/refractory chronic lymphocytic leukemia.